In a study published in Cell, Xu et al. (2008) raised the intriguing possibility that tyrosine residues present in the immunoreceptor tyrosine-based activation motifs (ITAMs) of the cytoplasmic domain of the CD33 subunit of the T cell receptor (TCR) are sequestered in the membrane. Here, they are inaccessible to tyrosine kinases that would otherwise drive signaling. As a consequence, the authors proposed that ''triggering'' of the TCR-that is, the events leading to phosphorylation of the receptor-must be dependent upon some, as yet undefined, process that liberates the ITAMs from the membrane. In an accompanying Preview, Kuhns and Davis (2008) invoked the idea that membrane association constitutes a ''safety catch'' that prevents untoward triggering of the TCR. Such effects add an additional layer of complexity to the TCR triggering problem.
Using equilibrium dialysis, Xu et al. showed that the cytoplasmic domain of CD33 (CD33CD) partitioned into acidic rather than zwitterionic lipids. They then went on to derive a structural model for ITAMs bound by acidic lipids using nuclear magnetic resonance (NMR)-based methods. A new in vivo FRETbased assay suggested that the association of the ITAM with the membrane was dependent on a cluster of positively charged residues in the membrane-proximal amino-terminal region of CD33CD; mutation of these residues reduced the association of CD33CD with the membrane as detected by the FRET assay. The obvious question was, does membrane association prevent kinases from accessing ITAMs in vivo? Xu et al. showed that the wild-type CD33 ITAM is not phosphorylated in resting T cells, implying that it may indeed be completely inaccessible to kinases. Somewhat surprisingly, however, they did not go on to clinch the argument by showing that there was increased phosphorylation of the membrane nonassociating CD33CD mutant. The results of this experiment turn out to be inconsistent with the predictions of Xu and colleagues.
To show that CD33CD is not phosphorylated in resting Jurkat T cells, Xu et al. used a chimeric protein consisting of murine CD33CD fused to the extracellular and transmembrane domains of the human natural killer cell inhibitory receptor KIR2DL3. We generated FLAG-tagged forms of this protein and a second chimera consisting of the extracellular and transmembrane domains of KIR2DL3 fused with CD33CD mutated at the set of clustered positively charged residues proposed to mediate membrane association, that is, the mutant Emut1+2 described by Xu et al. (see Experimental Procedures) . We expressed the two chimeras at similar levels in Jurkat T cells using a lentivirus expression system ( Figure S1A ) and probed for phosphorylation of CD33CD by western blotting ( Figure S1B ). Neither KIR2DL3/ CD33CD nor KIR2DL3/CD33CDEmut1+2 immunoprecipitated with anti-FLAG antibody showed detectable phosphorylation in resting T cells ( Figure S1B , lanes 1 and 2). Even after very long exposures of the blots, we were unable to detect phosphorylation over background levels of cross-reactivity of the antibody and we saw no differences in signal for the wildtype versus the mutant proteins (Figure S1B ). This was also the case for wild-type and Emut1+2-mutated forms of full-length CD33 incorporated into the TCR complex (data not shown).
These findings suggest either that the Emut1+2 mutations do not release the ITAMs from the membrane or that, in vivo, the association with the membrane is weaker than expected and some other process prevents CD33CD phosphorylation in resting cells. We suspected that tyrosine phosphatases might be responsible for the lack of phosphorylation of the wild-type and mutant forms of CD33CD. To test this, we incubated cells expressing the chimeric proteins with the tyrosine phosphatase inhibitor, pervanadate (Swarup et al., 1982) . Both the wild-type and mutated forms of CD33CD were heavily phosphorylated following incubation of the cells for 20 min with the inhibitor (Figure S1B, lanes 3 and 4) . Time course experiments indicated that rather than enhancing it, the Emut1+2 mutations somewhat slowed the kinetics of CD33CD phosphorylation (data not shown). In vivo, therefore, the wild-type form of CD33CD seemed to be at least as accessible to tyrosine kinases as the mutated, membrane nonassociating form of the protein when kinase activity could be observed by inhibiting phosphatase activity. Finally, CD33 was among the more heavily tyrosine phosphorylated proteins present in whole-cell lysates from pervanadate-treated wild-type Jurkat T cells ( Figure S1C ), emphasizing its accessibility to kinases relative to other kinase targets.
How can our observations be reconciled with those of Xu et al.? Our experiments suggest that membrane association, if it occurs, has less impact on CD33CD phosphorylation than might have been expected on the basis of the Xu et al. work. The strongest evidence for lipid association is, of course, the NMR structure of CD33CD stably bound to acidic lipids. It should be borne in mind, however, that we know little about the actual distribution of inner leaflet lipids around receptors embedded in the membrane. Recent work by Zech et al. (2009) shows that the acidic phospholipid phosphatidylserine is enriched in membrane sheets isolated from activated T cells using beads coated with anti-CD3 antibodies, but the extent to which this reflects the distribution of lipids in the immediate vicinity of the TCR in resting or activated cells is unclear. The density or properties of the acidic lipids adjacent to CD33 in resting cells might be insufficient to sustain an interaction of the type demonstrated in vitro by Xu et al. Whatever interaction ITAMs have with membranes in vivo might be too weak and dynamic to prevent access of the kinases.
The reasons for the low levels of CD33CD phosphorylation in resting T cells remain to be fully worked out. In any discussion of the possible constraints on tyrosine phosphorylation of the TCR, some consideration must be given to the protein tyrosine phosphatases (PTPs) present at the cell surface, such as CD45 (Hermiston et al., 2003) . Leukocytes express as many as 10 5 CD45 molecules, i.e., 2-3 for every TCR (Williams and Barclay, 1986), each with very broad substrate specificity (Barr et al., 2009) ; the catalytic activities of PTPs have been estimated to be 10-to 1000-fold higher than that of tyrosine kinases (discussed by Fischer et al., 1991) . Another contributing factor is the activity of inhibitory kinases such as Csk, which also constrain T cell activation (Schoenborn et al., 2009) . Progress in understanding TCR triggering will require the teasing apart of these and other competing factors and the identification of those factors with the largest impact on net phosphorylation of the TCR. The effects of pervanadate on phosphorylation levels in resting T cells observed by ourselves (Figures S1B and S1C) and by others many years ago (e.g., O'Shea et al., 1992) suggest that PTPs could be key. For us, the sheer weight of the numbers also warrants their serious consideration.
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